Pacific Biosciences of California Inc (PACB)

[Paulieme]

Michael Hunkapillar
100%
Approval Rating https://www.owler.com/iaApp/101491/pacific-biosciences-company-profile?utm_source=twitter&utm_medium=social&utm_campaign=mtcpc
Pacific Biosciences of California Upgraded to Buy at Zacks (PACB)

July 7th, 2015 -- Zacks upgraded shares of Pacific Biosciences of California (NASDAQ:PACB) from a hold rating to a buy rating in a research report released on Tuesday morning, Market Beat Ratings reports. Zacks currently has $6.00 price objective on the stock.

According to Zacks, “Pacific Biosciences reported dismal first-quarter 2015 results. The company reported net loss of $0.27 per share, in line with the Zacks Consensus Estimate but wider than the year-ago quarter loss. Nevertheless, we believe that Pacific Biosciences has significant growth prospects in plant & animal sequencing and human genome sequencing based on its SMRT technology. New products like the barcode sample prep kits continue to expand the company’s product portfolio. Additionally, development and distribution collaborations with the likes of Roche NimbleGen and RainDance Technologies will drive market penetration going forward. However, persistent losses and cash burning are the primary headwinds, in our view.” http://www.owler.com/iaApp/article/559c3e8de4b02f9936956e58.htm